Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy

#845

Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.

Aim(s): We investigated the relationship between response and Ki-67, and sought to define a cut-off for patient stratification.

Materials and methods: We reviewed data from 152 patients treated with 5-fluorouracil, cisplatin and streptozocin (FCiSt). Tumors were graded according to Ki-67 index: low ≤5%, intermediate 5-20% and high >20%. Radiological response was assessed by RECIST and survival calculated from start of chemotherapy to death. To explore the utility of Ki-67 as a marker of response, we calculated the likelihood ratio and performed receiver operating characteristic (ROC) analysis.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Childs A, Kirkwood A, Lee A, Caplin M, Gillmore R,

Keywords: chemotherapy, Ki-67,